Adipositas - Ursachen, Folgeerkrankungen, Therapie 2021; 15(03): 149-150
DOI: 10.1055/s-0041-1735669
Abstracts
Wiesbaden: Adipositas-Kongress 2021

4 Semaglutide 2.4 mg and Intensive Behavioral Therapy in Subjects With Overweight or Obesity (STEP 3)

Authors

  • Thomas Wadden

    1   University of Pennsylvania, Philadelphia, USA

  • Timothy Bailey

    2   AMCR Institute, Escondido, USA

  • Liana Billings

    3   NorthShore University HealthSystem/University of Chicago, Skokie, USA

  • Juan Frias

    4   National Research Institute, Los Angeles, USA

  • Anna Koroleva

    5   Novo Nordisk, Soborg, Dänemark

  • René Gollan

    6   Novo Nordisk, Mainz, Deutschland

  • Patrick O'neil

    7   Medical University of South Carolina, Charleston, USA

  • Domenica Rubino

    8   Washington Center for Weight Management and Research, Arlington, USA

  • Dorothe Skovgaard

    5   Novo Nordisk, Soborg, Dänemark

  • Signe Wallenstein

    5   Novo Nordisk, Soborg, Dänemark

  • Timothy Garvey

    9   University of Alabama, Birmingham, USA
Further Information
Also available at
 

Zusammenfassung

In adults with overweight or obesity, semaglutide 2.4 mg as an adjunct to IBT led to significantly greater weight loss and improvements in CVD risk factors and glucose metabolism vs. placebo plus IBT.



Publication History

Article published online:
24 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany